Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22) - Université de Bourgogne Accéder directement au contenu
Communication Dans Un Congrès Année : 2017

Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22)

A. Luciani

Domaines

Cancer

Dates et versions

hal-01632311 , version 1 (10-11-2017)

Identifiants

Citer

M. Karoui, A. Rullier, C. Mariette, E. Maillard, A. Bardier, et al.. Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22). the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. pp.476O, ⟨10.1093/annonc/mdx393.003⟩. ⟨hal-01632311⟩
63 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More